{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:28Z","timestamp":1771824508877,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejmech.2023.115256","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T03:15:13Z","timestamp":1678331713000},"page":"115256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Design, synthesis, and repurposing of O-aminoalkyl-sulfuretin analogs towards discovery of potential lead compounds as antileishmanial agents"],"prefix":"10.1016","volume":"251","author":[{"given":"Ahmed H.E.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trong-Nhat","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyeon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chae Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Bin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selwan M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeonwoo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Hwan","family":"No","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-6979","authenticated-orcid":false,"given":"Yong Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115256_bib1","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/14756366.2021.1969385","article-title":"Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani","volume":"36","author":"Hassan","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115256_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3201\/eid1404.071099","article-title":"Kala-azar epidemiology and control, southern Sudan","volume":"14","author":"Kolaczinski","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ejmech.2023.115256_bib3","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/IDR.S245991","article-title":"Incidence of mortality and its predictors among adult visceral leishmaniasis patients at the university of gondar hospital: a retrospective cohort study","volume":"13","author":"Yeshaw","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ejmech.2023.115256_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115256_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1039\/D1NP00039J","article-title":"Cheminformatic analysis of natural product-based drugs and chemical probes","volume":"39","author":"Stone","year":"2022","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2023.115256_bib7","doi-asserted-by":"crossref","first-page":"nwac206","DOI":"10.1093\/nsr\/nwac206","article-title":"Natural products and drug discovery","volume":"9","author":"Newman","year":"2022","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.ejmech.2023.115256_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115256_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2023.115256_bib10","series-title":"Sustainable Agriculture Reviews 43: Pharmaceutical Technology for Natural Products Delivery","first-page":"33","article-title":"Solubility enhancement techniques for natural product delivery","volume":"1","author":"Jain","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115256_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10311-020-01082-x","article-title":"Methods to improve the solubility of therapeutical natural products: a review","volume":"19","author":"Jain","year":"2021","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115256_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115256_bib13","series-title":"The Medicinal Chemist\u2019s Guide to Solving ADMET Challenges","first-page":"16","article-title":"Chapter 2: Tactics to improve solubility","author":"Young","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115256_bib14","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.drudis.2022.02.007","article-title":"Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives","volume":"27","author":"Huang","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115256_bib15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.drudis.2022.05.026","article-title":"Drug repurposing: an effective strategy to accelerate contemporary drug discovery","volume":"27","author":"Zhan","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115256_bib16","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/molecules25051154","article-title":"Repositioning natural products in drug discovery","volume":"25","author":"Rastelli","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115256_bib17","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2023.115256_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.ejmech.2023.115256_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Charlton","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2023.115256_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115256_bib21","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2023.115256_bib22","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3390\/molecules25051239","article-title":"Multitargeting compounds: a promising strategy to overcome multi-drug resistant tuberculosis","volume":"25","author":"Stelitano","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115256_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13148-016-0271-9","article-title":"Epigenetic polypharmacology: from combination therapy to multitargeted drugs","volume":"8","author":"de Lera","year":"2016","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2023.115256_bib24","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115256_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-3024.2001.00372.x","article-title":"Leishmania donovani-induced macrophages cyclooxygenase-2 and prostaglandin E2 synthesis","volume":"23","author":"Matte","year":"2001","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.ejmech.2023.115256_bib26","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1400399","article-title":"Prostaglandin E2 negatively regulates the production of inflammatory cytokines\/chemokines and IL-17 in visceral leishmaniasis","volume":"193","author":"Saha","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115256_bib27","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1128\/IAI.00528-16","article-title":"Leishmania donovani-induced prostaglandin E2 generation is critically dependent on host toll-like receptor 2\u2013cytosolic phospholipase A2 signaling","volume":"84","author":"Bhattacharjee","year":"2016","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2023.115256_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1034\/j.1600-0463.2001.091201.x","article-title":"Purification and enzymatic activity of an NADH-fumarate reductase and other mitochondrial activities of Leishmania parasites","volume":"109","author":"Chen","year":"2001","journal-title":"APMIS"},{"key":"10.1016\/j.ejmech.2023.115256_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0166-6851(95)02510-3","article-title":"Characterization of the respiratory chain of Leishmania donovani promastigotes","volume":"75","author":"Santhamma","year":"1995","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2023.115256_bib30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/ph15091058","article-title":"Design, rational repurposing, synthesis, in vitro evaluation, homology modeling and in silico study of sulfuretin analogs as potential antileishmanial hit compounds","volume":"15","author":"Hassan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.115256_bib31","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00706-013-1024-5","article-title":"A comparative study on the antioxidant properties of bractein and cernuoside by the DFT method","volume":"144","author":"Senthil kumar","year":"2013","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2023.115256_bib32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0014-5793(00)01211-4","article-title":"Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase","volume":"468","author":"Day","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ejmech.2023.115256_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bmc.2014.11.004","article-title":"Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors","volume":"23","author":"Lee","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115256_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/903529","article-title":"The antiacetylcholinesterase and antileishmanial activities of Canarium patentinervium Miq","volume":"2014","author":"Mogana","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2023.115256_bib35","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/12081548","article-title":"Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera","volume":"12","author":"Lenta","year":"2007","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115256_bib36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1590\/S0100-736X2012001100015","article-title":"Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds of Dimorphandra gardneriana and Platymiscium floribundum, native plants from Caatinga biome","volume":"32","author":"Vila-Nova","year":"2012","journal-title":"Pesqui. Vet. Bras."},{"key":"10.1016\/j.ejmech.2023.115256_bib37","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1021\/jo1006812","article-title":"Aiming for the ideal synthesis","volume":"75","author":"Gaich","year":"2010","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115256_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2019.130760","article-title":"An expeditious entry to rare tetrahydroimidazo[1,5-c]pyrrolo[1,2-a]pyrimidin-7(8H)-ones: a single-step gateway synthesis of glochidine congeners","volume":"75","author":"Seo","year":"2019","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2023.115256_bib39","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/acs.orglett.8b00098","article-title":"Construction of 8-azabicyclo[3.2.1]octanes via sequential DDQ-mediated oxidative mannich reactions of N-aryl pyrrolidines","volume":"20","author":"Jo","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2023.115256_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136891","article-title":"Metabolomic analyses of leishmania reveal multiple species differences and large differences in amino acid metabolism","volume":"10","author":"Westrop","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.115256_bib41","first-page":"27","article-title":"Nishi, Visceral leishmaniasis: experimental models for drug discovery","volume":"133","author":"Gupta","year":"2011","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2023.115256_bib42","series-title":"Clinical Pharmacy Education, Practice and Research","first-page":"409","article-title":"Chapter 29 - clinical pharmacokinetics","author":"Miah","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115256_bib43","series-title":"Handbook of Pharmacogenomics and Stratified Medicine","first-page":"365","article-title":"Chapter 18 - pharmacodynamic pharmacogenomics","author":"McCallum","year":"2014"},{"key":"10.1016\/j.ejmech.2023.115256_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005805","article-title":"Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine","volume":"11","author":"Villa-Pulgar\u00edn","year":"2017","journal-title":"PLoS Neglected Trop. Dis."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423002222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:50:39Z","timestamp":1759330239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423002222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"alternative-id":["S0223523423002222"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115256","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and repurposing of O6-aminoalkyl-sulfuretin analogs towards discovery of potential lead compounds as antileishmanial agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115256"}}